Ibogaine for Opioid Addiction: What the Evidence Really Shows

Opioid use disorder, including dependence on heroin, prescription painkillers and fentanyl, is the condition for which ibogaine has the strongest evidence. In observational studies from Mexico and New Zealand, a single ibogaine treatment eliminated or sharply reduced withdrawal for most patients and helped a meaningful share stop or reduce opioid use for months. It is not FDA-approved, it carries real cardiac risk and it is not a guaranteed cure, but for people who have not succeeded with other treatments it is a serious option when done under medical supervision.

Key takeaways

• A 2022 systematic review covered 24 studies and 705 people treated with ibogaine or noribogaine, most for opioid dependence.
• In a Mexican study of 50 patients, about 78% had no objective signs of withdrawal 48 hours after ibogaine.
• In a 30-patient Mexican study, 50% reported no opioid use in the month after treatment; in a New Zealand study, a single treatment led to stopping or reducing use over 12 months.
• Relapse is common without aftercare: in a survey of 88 patients, 70% relapsed at some point, but 48% still used less than before.
• Ibogaine's main risk is cardiac, so screening and continuous heart monitoring are essential.

How ibogaine acts on opioid dependence

Unlike methadone or buprenorphine, ibogaine is not an opioid replacement. It acts on several brain systems at once, including opioid, NMDA, serotonin and nicotinic receptors. Researcher Kenneth Alper described it as resolving the signs of opioid withdrawal "by a mechanism that is different from an opioid effect." Its long-acting metabolite, noribogaine, remains in the body for days and is thought to explain the reduced cravings many patients describe afterwards.

Patients also describe a long, introspective experience in which they review memories and the reasons behind their use. Many say this changed how they see their addiction, although this is harder to measure.

What the studies show

A 2022 systematic review of clinical studies (24 studies, 705 people) concluded that ibogaine appears effective at reducing withdrawal symptoms and cravings, while warning about serious adverse events, including deaths, in poorly supervised settings. A 2023 review in Current Neuropharmacology reached a similar conclusion and called for controlled trials.

Honest limitations

• Most studies are observational, without placebo or control groups.
• Samples are small, and patients chose to pay for treatment, which may make them more motivated than average.
• Relapse happens. Ibogaine interrupts withdrawal and cravings, but long-term recovery depends on what comes next.

Ibogaine is best understood as a powerful starting point, not a complete treatment.

Ibogaine compared with methadone and Suboxone

Methadone and buprenorphine are proven, FDA-approved treatments that reduce overdose deaths, and they are the right choice for many people. Ibogaine is different: it aims to interrupt dependence in a single treatment rather than maintain it. People who want to come off maintenance medication need a carefully planned transition, because those medications act for a long time. We compare both approaches in detail in ibogaine vs. methadone and Suboxone. For fentanyl, see ibogaine for fentanyl addiction.

Safety: what must be in place

• Cardiac screening: an EKG, electrolytes, liver tests and a medication review before treatment.
• Continuous monitoring: ibogaine temporarily prolongs the QT interval, so heart rhythm should be monitored throughout and for hours afterwards.
• No opioids during treatment: combining opioids with ibogaine can be fatal.
• Overdose prevention afterwards: tolerance falls after detox, so a previous dose can be lethal. Naloxone and a relapse plan are essential.

Read more in ibogaine side effects and heart safety.

What makes results last

Patients who do best usually combine treatment with therapy, peer support, a stable place to live, changes in their social circle and a plan for stressful moments. In the Davis survey, people who did well also reported lasting changes in how they coped with stress and difficult feelings. That is why our program includes a 90-day aftercare plan, not just the treatment week.

At Ibogaine Center Cancún, treatment is overseen by an on-site cardiologist, with continuous EKG telemetry and one-to-one ACLS nursing, in a clinic limited to six patients. See what to expect during 7 days and the cost of treatment.

See how treatment works, what is included and who can apply in our ibogaine program for opioid and fentanyl addiction.

Frequently asked questions

What is the success rate of ibogaine for opioid addiction?

There is no single figure. In studies, most patients had little or no withdrawal within 48 hours, about half were opioid-free a month later in one study, and a smaller share stayed abstinent long term. Results depend greatly on aftercare and personal circumstances.

Can one ibogaine treatment end opioid withdrawal?

For many patients, a single treatment eliminates or greatly reduces withdrawal. Long-acting opioids such as methadone and fentanyl may require a transition period before treatment and sometimes extra support afterwards.

Does ibogaine work for prescription painkillers like oxycodone?

Yes, the studies included people dependent on prescription opioids as well as heroin. If you have chronic pain, your pain management plan must be reviewed before treatment.

Is it safe to take ibogaine while on methadone or Suboxone?

Not without a medical transition. Both medications act for a long time and must be managed by your doctor and our medical team before ibogaine.

Will I relapse after ibogaine?

Some people do. Ibogaine gives you a window with less withdrawal and fewer cravings; what you build during that window, with therapy and support, largely decides the long-term outcome.

References

• Köck, P. et al. "A systematic literature review of clinical trials and therapeutic applications of ibogaine." Journal of Substance Abuse Treatment, 2022. PubMed
• Mosca, A. et al. "Ibogaine/Noribogaine in the treatment of substance use disorders: a systematic review of the current literature." Current Neuropharmacology, 2023.
• Malcolm, B. J., Polanco, M., Barsuglia, J. P. "Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine." Journal of Psychoactive Drugs, 2018. PubMed
• Brown, T. K., Alper, K. "Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes." American Journal of Drug and Alcohol Abuse, 2018. PubMed
• Noller, G. E. et al. "Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study." American Journal of Drug and Alcohol Abuse, 2018.
• Davis, A. K. et al. "Subjective effectiveness of ibogaine treatment for problematic opioid consumption." Journal of Psychedelic Studies, 2017.

Ready to talk about opioid treatment? Start with a confidential medical evaluation. Our team will tell you honestly whether ibogaine is right for you. Request your evaluation.